

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CLARIFICATION ANNOUNCEMENT IN RELATION TO ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2017**

Reference is made to the annual report for the year ended 31 December 2017 (“**Annual Report**”) of China NT Pharma Group Company Limited (“**Company**”) published on 27 April 2018. Capitalised terms used in this announcement shall have the same meanings as those defined in the Annual Report unless otherwise defined herein.

The board of directors of the Company wishes to clarify and confirm the followings contained in page 66 and 67 of the Annual Report:

1. Under the section headed “DIRECTORS’ AND CHIEF EXECUTIVE’S INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY OR ITS ASSOCIATED CORPORATIONS” in page 66, Mr. Yu Tze Shan, Hailson, an independent non-executive Director personally held 150,000 shares of the Company which represented 0.01% interest of the Company.

2. Under the section headed “SUBSTANTIAL SHAREHOLDERS” in page 67, the table for the Substantial Shareholders’ Interests and Short Positions in Shares and Underlying Shares of the Company shall be amended and be replaced as follows:

### Long position in shares of the Company

Name	Beneficial owner	Interests of controlled corporation	Family interests	Investment Manager	Approximate percentage of interest in issued ordinary shares of the Company	Approximate percentage of interests in issued convertible preference shares of the Company
Golden Base	602,092,000	–	–	–	38.63%	–
Shanghai Jiao Da Onlly Co., Limited* (Note 1)	175,829,000	182,090,000 (Note 1)	–	–	22.97%	–
Ieong Chong Mang	45,381,500	–	220,279,000 (Note 2)	–	3.02% (Note 2)	74.18% (Note 2)
Shum Ning	–	220,279,000 (Note 2)	45,381,500 (Note 3)	–	3.02% (Note 2)	74.18% (Note 2)
GLB Capital	–	–	–	93,136,500 (Note 4)	5.98%	–

#### Notes:

- 182,090,000 ordinary shares are beneficially owned by Onlly International Investment (HK) Limited, which is in turn wholly-owned by Shanghai Jiao Da Onlly Co., Ltd\*.
- These 220,279,000 shares are beneficially owned by Annie Investment Co., Ltd., which is in turn wholly owned by Shum Ning. Under the Securities and Futures Ordinance (the “SFO”), Shum Ning is deemed to be interested in all the shares in which Annie Investment Co., Ltd. is interested. Of the 220,279,000 shares, 1,700,000 shares are ordinary shares and 218,579,000 shares are convertible preference shares.
- Shum Ning is the spouse of Ieong Chong Mang. Under the SFO, Shum Ning is deemed to be interested in 45,381,500 ordinary shares in which Ieong Chong Mang is interested. Likewise, under the SFO, Ieong Chong Mang is deemed to be interested in 1,700,000 ordinary shares and 218,579,000 convertible preference shares owned by Annie Investment Co., Ltd. which are deemed to be owned by Shum Ning.
- These ordinary shares are held by GLB Capital in its capacity as investment manager.

\* For identification purposes only

Save as disclosed above, all other information and contents set out in the Annual Report remain unchanged.

By Order of the Board  
**China NT Pharma Group Company Limited**  
**Ng Tit**  
*Chairman*

Hong Kong, 11 May 2018

*As at the date of this announcement, the executive Directors are Mr. Ng Tit, Ms. Chin Yu and Mr. Wu Weizhong; the non-executive Directors are Dr. Qian Wei and Ms. Lou Jianying; and independent non-executive Directors are Mr. Tze Shan Hailson Yu, Mr. Patrick Sun, and Dr. Lap-Chee Tsui.*